2.
Imatinib及sunitinib联合化疗治疗NSCLC临床试验汇总表
The clinical trials of sunitinib or imatinib administrated in combined with chemotherapy in NSCLC
| First author | Year | Phase | Criteria | n | Regimen | RR (95%CI or P) | mPFS (95% CI or P) |
mOS (95% CI or P) |
| 1/2: One week for chemotherapy treatment, followed by two weeks of no treatment. 2/1: Two consecutive weeks for once daily treatment, followed by two weeks of no treatment. 3/1: Three weeks for weekly paclitaxel therapy, followed by one week of no treatment. CD: continuous daily dosing with no interval. a: one in twenty-three achieved PR. b: one in twenty-one achieved PR. -: data were not available. PD: Pulse dose bracketing each paclitaxel infusion. RR means response rate which is express in percentage, and the unit of survival time (median progression-free survival and median overall survival) is week. | ||||||||
| Martin Reck[32] | 2010 | Ⅰ | Ⅲb, Ⅳ, no prior treatment | 28 | GP (gemstabin+cisplatin) 1/2+Sn CD/2/1 | 20.8 (-) | - | - |
| Mark A. Socinski[44] | 2010 | Ⅱ | Ⅲb, Ⅳ | 56 | TCB (paclitaxel+caborplatin+bevacizumab) 1/2±Sn 2/1 | 8 vs 26（-） | 15.2 vs 18.0（-） | 26.4 vs - |
| Chao H. Huang[45] | 2011 | Ⅱ | Relapse or Progress | 23 | Docetaxel 30 mg/m2 3/1+Im 600 mg/d | 1/23a | 7.6 (-) | 24.4 (-) |
| Anne S. Tsao[28] | 2011 | Ⅱ | metastasis | 22 | Docetaxel 60 mg/m2 1/2+Im 400 mg/d | 1/22b | 7.9 (-) | 35.6 (-) |
| Julie E. Bauman[29] | 2012 | Ⅱ | Ⅲb, Ⅳ, no prior treatment | 34 | Paclitaxel 90 mg/m2 3/1+Im 600 mg/d PD | 32 (17, 51) | 14.4 (-) | 29.2 (-) |
| L. Q. M. Chow[31] | 2012 | Ⅰ | Recurrent or advanced | 21 | Pemetrexed 1/2+Sn CD/2/1 | 24 (-) | - | - |
| D. Ross Camidge[30] | 2013 | Ⅰ | Recurrent or advanced | 15 | AP (pemetrexed+cisplatin) 1/2+Sn CD/2/1 | - | - | - |